Abstract 131P
Background
Trop 2 is a transmembrane intracellular signal transducer glycoprotein related to tumor proliferation. Targeting therapy against Trop2 is limited only to triple-negative breast cancer, but its role in mCRC remains poorly defined. The aim of this study is to elucidate Trop2’s biological role in mCRC, its prognostic and therapeutic implication.
Methods
We investigated prospectively 56 consecutive mCRCp from January 2016 to May 2023 and we analyzed respectively tissues from primary tumor (n.56) and synchronous and metachronous metastastic lesions (n.336). The specimens immunohistochemically stained for Trop2, Kras, B-raf, MSI and HER-2 were reviewed. We evaluated the Trop2 H-score distribution in the three cohorts: (1) primary tumor, (2) visceral metastases, (3) bone metastases and the different sites were divided in two groups based on Trop2 expression (high vs low). Clinic-pathological features were also matched with genomic and expression profiles.
Results
Moderate to strong membranous expression of Trop2 in at least 10% of tumor cells was present in 13/56 cases (23.2%) of cohort 1, 80/256 cases (31.2%) of cohort 2, and 71/80 cases (87.6%) of cohort 3. There was no difference in Trop2 H-score distribution between cohort 1 and 2 (Mann Whitney U test p=.966) but it is statistically different when combining cumulative data of cohort 1 and 2 vs cohort 3 (Mann Whitney U p<0.01). High Trop2 Score was significantly correlated with increased K-ras and B-raf mutational status, 83% vs 17% (Mann Whitney U p<0.01), and it was an independent poor prognostic factor for overall survival in cohort 3. No correlations were seen with MSI and HER-2 status.
Conclusions
Trop2 expression is a strong prognostic biomarker for bone mCRC. In bone metastatic disease Trop2 expression could induce a different biological aggressiveness, causing resistance to common therapeutic drugs and radiotherapy. Targeting Trop2 might be a useful treatment approach for these patients but further evaluations and clinical trials on efficacy and predictive value of Trop2 expression are needed.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
BMAT ILAB s.r.l.s.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract